577 related articles for article (PubMed ID: 26027692)
1. Pharmacologic treatment options for advanced epithelial skin cancer.
Soura E; Chasapi V; Stratigos AJ
Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
[TBL] [Abstract][Full Text] [Related]
2. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Rudnick EW; Thareja S; Cherpelis B
Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
4. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
6. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
Ruiz Salas V; Alegre M; Garcés JR; Puig L
Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
Lyons TG; O'Kane GM; Kelly CM
Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
11. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
13. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
14. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
Sobanko JF; Okman J; Miller C
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
17. Basal cell carcinoma: a paradigm for targeted therapies.
Dreier J; Felderer L; Barysch M; Rozati S; Dummer R
Expert Opin Pharmacother; 2013 Jul; 14(10):1307-18. PubMed ID: 23656611
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Gaffney DC; Soyer HP; Simpson F
Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
Yin VT; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
[TBL] [Abstract][Full Text] [Related]
20. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]